Future AI Will Most Likely Predict Antibody-Drug Conjugate Response in Oncology: A Review and Expert Opinion
Cancers · 05.09.2024 · 16 (17) · 3089
DOI: 10.3390/cancers16173089 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.09.2024. Verfasst von Navid Sobhani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The medical research field has been tremendously galvanized to improve the prediction of therapy efficacy by the revolution in artificial intelligence (AI). An earnest desire to find better ways to predict the effectiveness of therapy with the use of AI has propelled the evolution of new models in which it can become more applicable in clinical settings such as breast cancer detection. However, in some instances, the U.S. Food and Drug Administration was obliged to back some previously approved inaccurate models for AI-based prognostic models because they eventually produce inaccurate prognoses for specific patients who might be at risk of heart failure. In light of instances in which the medical research community has often evolved some unrealistic expectations regarding the advances in AI and its potential use for medical purposes, implementing standard procedures for AI-based cancer models is critical. Specifically, models would have to meet some general parameters for standardization, transparency of their logistic modules, and avoidance of algorithm biases. In this review, we summarize the current knowledge about AI-based prognostic methods and describe how they may be used in the future for predicting antibody-drug conjugate efficacy in cancer patients. We also summarize the findings of recent late-phase clinical trials using these conjugates for cancer therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Medicine, Northern General Hospital, Sheffield S5 7AT, UK.
- Department of Surgery, Oncology and Gastroenterology, University of Padova, 35122 Padova, Italy.
- Royal Infirmary Hospital, Foresterhill Health Campus, Aberdeen AB25 2ZN, UK.
- Department of Medicine, Surgery and Health Sciences, University of Trieste, 34100 Trieste, Italy.
ORCID-Profile: Navid Sobhani, Matteo Pittacolo, Giuseppina Mondani, Daniele Generali
Zitieren
APA
Sobhani, N., D'Angelo, A., Pittacolo, M., Mondani, G., & Generali, D. (2024). Future AI Will Most Likely Predict Antibody-Drug Conjugate Response in Oncology: A Review and Expert Opinion. Cancers, 16(17), 3089. https://doi.org/10.3390/cancers16173089
Vancouver
Sobhani N, D'Angelo A, Pittacolo M, Mondani G, Generali D. Future AI Will Most Likely Predict Antibody-Drug Conjugate Response in Oncology: A Review and Expert Opinion. Cancers. 2024;16(17):3089. doi:10.3390/cancers16173089
BibTeX
@article{Sobhani2024,
author = {Sobhani, Navid and D'Angelo, Alberto and Pittacolo, Matteo and Mondani, Giuseppina and Generali, Daniele},
title = {Future AI Will Most Likely Predict Antibody-Drug Conjugate Response in Oncology: A Review and Expert Opinion},
journal = {Cancers},
year = {2024},
volume = {16},
number = {17},
pages = {3089},
doi = {10.3390/cancers16173089}
}
EUVIMED